Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Loss of response after switching from Humira to Amgevita versus continuing Humira in inflammatory bowel disease
2019-000717-37Phase 4Terminated
- Sponsor
- Fundación Pública Andaluza para la Gestión de la Investigación
- Start
- Jun 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of adalimumab in Crohn's disease, autoimmune colitis and inflammatory bowel disease (IBD) (2 arms), sponsored by Fundación Pública Andaluza para la Gestión de la Investigación. Started Jun 2019; status: terminated.
02
Drugs
03
Conditions
Crohn's diseaseautoimmune colitisinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on 2019-000717-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000717-37.